Rappta Therapeutics, a company developing anti-cancer drugs, has entered a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies are developed using high resolution structural data and have the potential to create a new class of anti-cancer drugs for treating a broad […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!